Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:23 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 9,138 matching trials from the live ClinicalTrials.gov search.
Filters: Rochester, Minnesota Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes

NCT01021865
View directory record Official record
Conditions
Coronary Artery Disease, Diabetes Mellitus Type 2
Interventions
Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Nov 3, 2026, 6:23 AM EST
Completed No phase listed Observational Results available

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

NCT01099267
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
14
States / cities
Scottsdale, Arizona • Stanford, California • Lecanto, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Nov 3, 2026, 6:23 AM EST
Terminated Not applicable Interventional Results available

Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity

NCT03261531
View directory record Official record
Conditions
Obesity
Interventions
Transcutaneous electrical nerve stimulation (TENS)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Nov 3, 2026, 6:23 AM EST
Terminated Phase 1 Interventional

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

NCT05388877
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Melanoma
Interventions
Dabrafenib, MEK-1/MEKK-1 Inhibitor E6201, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Nov 3, 2026, 6:23 AM EST
Terminated Phase 3 Interventional

A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack

NCT00112281
View directory record Official record
Conditions
Shock, Cardiogenic
Interventions
Tilarginine Acetate Injection intravenous infusion
Drug
Lead sponsor
Arginox Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
83
States / cities
Mobile, Alabama • Fort Smith, Arizona • Mesa, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Nov 3, 2026, 6:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Activity Monitoring and Counseling in a Geriatric Population

NCT01502007
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Accelerometer feedback and lifestyle counseling, Accelerometer without Feedback
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Nov 3, 2026, 6:23 AM EST
Completed Not applicable Interventional Results available

Correlation of Spinopelvic Movement With Lateral Radiographs

NCT05117229
View directory record Official record
Conditions
Spinopelvic Relationships as They Relate to Total Hip Arthroplasty's
Interventions
MetaWear Sensor
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 1 Interventional

Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy

NCT00805753
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
ACTH
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Nov 3, 2026, 6:23 AM EST
Recruiting Phase 2 Interventional

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739
View directory record Official record
Conditions
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 6:23 AM EST
Withdrawn Not applicable Interventional

Aliskiren in Patients With Idiopathic Membranous Nephropathy

NCT01093781
View directory record Official record
Conditions
Idiopathic Membranous Nephropathy
Interventions
Aliskiren
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Nov 3, 2026, 6:23 AM EST
Not yet recruiting Not applicable Interventional

Dorsal Root Ganglion Stimulation After Lower Motor Neuron Damage

NCT07619300
View directory record Official record
Conditions
Spinal Cord Injuries, Lower Motor Neuron Disease
Interventions
Abbot Dorsal Root Ganglion Neurostimulator
Device
Lead sponsor
Peter J. Grahn, Ph.D.
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 3, 2026, 6:23 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses

NCT03735407
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
C-Scan procedure
Device
Lead sponsor
Check-Cap Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 2 Interventional

A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment

NCT00000671
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
70
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Nov 3, 2026, 6:23 AM EST
Withdrawn Early Phase 1 Interventional

Electrocardiographic Mapping and Imaging

NCT01394965
View directory record Official record
Conditions
Cardiac Arrhythmia
Interventions
ECG electrodes
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 2 Interventional Results available

The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction

NCT02554253
View directory record Official record
Conditions
Cognitive Disorders, Delirium, Acute Kidney Injury
Interventions
Ketamine, Propofol
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 4 Interventional

CATIE- Schizophrenia Trial

NCT00014001
View directory record Official record
Conditions
Schizophrenia
Interventions
perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, clozapine, fluphenazine decanoate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
54
States / cities
Chula Vista, California • Los Angeles, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 3 Interventional

Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva

NCT00028951
View directory record Official record
Conditions
Lymphedema, Perioperative/Postoperative Complications, Vulvar Cancer
Interventions
fibrin sealant, surgical wound closure
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 3 Interventional Results available

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Nov 3, 2026, 6:23 AM EST
Temporarily Not Available No phase listed Expanded access

Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty

NCT06383611
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
VT-X7 Treatment System
Combination Product
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Grand Junction, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 6:23 AM EST
Recruiting Phase 2 Interventional

Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors

NCT06028022
View directory record Official record
Conditions
Estrogen Receptor-Positive Breast Carcinoma
Interventions
Mushroom Extract, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
23
States / cities
Albert Lea, Minnesota • Baxter, Minnesota • Bemidji, Minnesota + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 6:23 AM EST
Completed Not applicable Interventional

Transfusion-Induced Alterations of Pulmonary and Immune Function in Mechanically Ventilated Patients

NCT00751322
View directory record Official record
Conditions
Pulmonary Edemas, Blood Protein Disorders
Interventions
RBC transfusion of 5 days or less storage age, RBC transfusion of conventional storage age
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Nov 3, 2026, 6:23 AM EST
Terminated Phase 2 Interventional Results available

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

NCT01065051
View directory record Official record
Conditions
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 3, 2026, 6:23 AM EST
Not listed Phase 4 Interventional

Struvite Stones Antibiotic Study

NCT02375295
View directory record Official record
Conditions
Kidney Stones
Interventions
ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
11
States / cities
Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Nov 3, 2026, 6:23 AM EST
Completed Phase 3 Interventional Results available

Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer

NCT02908477
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Adjuvant Radiation Therapy, Docetaxel, Cisplatin
Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 3, 2026, 6:23 AM EST